ARCT SEC Filing News — Arcturus Therapeutics Holdings Inc.

Latest SEC filings for Arcturus Therapeutics Holdings Inc. (ARCT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-23.

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address orni…
Sector: Healthcare Industry: Biotechnology Market Cap: $312.1M
20
Total Filings
0
Bullish Classifications
0
Bearish Classifications
10
Insider Transactions
7
Material Events (8-K)
3
Periodic Reports
What you're looking at: Each item below is parsed from an actual SEC filing submitted by Arcturus Therapeutics Holdings Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.
ARCT Filing Activity Snapshot 2025-12-19 — 2026-09-23
Insider Transactions (Form 4)
0 buys vs 0 sells
Insider buying and selling activity is balanced in this period.
Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for Arcturus Therapeutics Holdings Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 10 compensation award. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Compensation award ×10
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

HOLMES EDWARD W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock option (right to buy) 15,000 — —
Filing: Form 4 (Insider Transaction) Insider: HOLMES EDWARD W (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

FARRELL PETER C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock option (right to buy) 15,000 — —
Filing: Form 4 (Insider Transaction) Insider: FARRELL PETER C (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

BARLOW JAMES F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock option (right to buy) 15,000 — —
Filing: Form 4 (Insider Transaction) Insider: BARLOW JAMES F (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

Markels John (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock option (right to buy) 15,000 — —
Filing: Form 4 (Insider Transaction) Insider: Markels John (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

Slaoui Moncef (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock option (right to buy) 15,000 — —
Filing: Form 4 (Insider Transaction) Insider: Slaoui Moncef (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

Marquet Magda (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock option (right to buy) 15,000 — —
Filing: Form 4 (Insider Transaction) Insider: Marquet Magda (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-15

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

Marantz Jing L. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock option (right to buy) 15,000 — —
Filing: Form 4 (Insider Transaction) Insider: Marantz Jing L. (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-07

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

MULROY DENNIS (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Employee Stock Option (right to buy) 100,000 — —
Filing: Form 4 (Insider Transaction) Insider: MULROY DENNIS (Chief Financial Officer)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2025-12-19

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

Roberts Joseph (Controller) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Employee Stock Option (right to buy) 10,000 — —
Filing: Form 4 (Insider Transaction) Insider: Roberts Joseph (Controller)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2025-12-19

ARCT insider Form 4 filed for equity award, exercise, or tax withholding

Chivukula Pad (Chief Scientific Officer & COO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Employee Stock Option (right to buy) 54,000 — —
Filing: Form 4 (Insider Transaction) Insider: Chivukula Pad (Chief Scientific Officer & COO)
View on SEC EDGAR → Open Filing Document →
Material Events 7 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 7 in this period for Arcturus Therapeutics Holdings Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-23

ARCT filed 8-K — material company event

Arcturus Therapeutics Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-25

ARCT filed 8-K — material company event

Arcturus Therapeutics Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-06

ARCT filed 8-K — material company event

Arcturus Therapeutics Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-02

ARCT filed 8-K — material company event

Arcturus Therapeutics Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-05

ARCT filed 8-K — material company event

Arcturus Therapeutics Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-07

ARCT filed 8-K — material company event

Arcturus Therapeutics Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-03-03

ARCT filed 8-K — material company event

Arcturus Therapeutics Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for Arcturus Therapeutics Holdings Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

ARCT filed Quarterly Report (10-Q)

Arcturus Therapeutics Holdings Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 10-Q Quarterly Report 2026-05-07

ARCT filed Quarterly Report (10-Q)

Arcturus Therapeutics Holdings Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 10-K Annual Report 2026-03-03

ARCT filed Annual Report (10-K)

Arcturus Therapeutics Holdings Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)
View on SEC EDGAR → Open Filing Document →

How we classify Arcturus Therapeutics Holdings Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on ARCT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — ARCT SEC Filings

More Tools for ARCT

ARCT Full Stock Analysis ARCT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper ARCT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the ARCT stock analysis page.

ARCT Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer